Patents Assigned to Peter MacCallum Cancer Institute
-
Patent number: 11866504Abstract: The present application is directed to bispecific polypeptides comprising a first domain binding an antigen on an antigen presenting cell (ARC) and a second domain binding an antigen on an immune cell expressing a chimeric antigen receptor (CAR). Nucleic acids, vectors and host cells used in producing the polypeptide of the invention are also disclosed. Compositions comprising the bispecific polypeptides and methods of treating cancer and stimulating activation and expansion of immune cells in vivo and in vitro are also disclosed.Type: GrantFiled: October 29, 2019Date of Patent: January 9, 2024Assignee: Peter MacCallum Cancer InstituteInventors: Michael Kershaw, Clare Slaney, Bianca Von Scheidt
-
Patent number: 11828759Abstract: The present invention relates generally to a method of detecting a risk of the progression from a pre-invasive neoplasia of the glandular epithelium. More particularly, the present invention provides a method of detecting a risk of the progression from a pre-invasive breast neoplasia by screening for the level of expression of Stefin A in the myoepithelial cells. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, predicting the likelihood of a subject progressing to a more advance disease state or informing decisions in relation to the design of treatment schedules.Type: GrantFiled: February 10, 2017Date of Patent: November 28, 2023Assignee: Peter MacCallum Cancer InstituteInventors: Belinda Sheree Parker, Hendrika Martha Duivenvoorden
-
Publication number: 20230293478Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).Type: ApplicationFiled: May 12, 2021Publication date: September 21, 2023Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer InstituteInventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
-
Patent number: 11243205Abstract: The present invention relates generally to a method of prognosing the survival of a patient with a breast neoplasm, more particularly a patient with a breast neoplasm which is estrogen receptor-/progesterone receptor-/HER-2-(“triple-negative”). The method of the present invention more particularly provides a method for prognosing breast cancer patient survival, in particular risk of metastatic spread, by screening for IRF9 expression. In a related aspect, the present invention provides a method of therapeutically or prophylactically treating patients with a triple-negative breast neoplasm, in particular those patients with triple-negative breast neoplasia which is characterised by a poor survival prognosis, still more particularly a high risk of metastatic spread, by upregulating type I IFN levels.Type: GrantFiled: May 20, 2016Date of Patent: February 8, 2022Assignee: Peter MacCallum Cancer InstituteInventor: Belinda Sheree Parker
-
Publication number: 20220017628Abstract: The present application is directed to bispecific polypeptides comprising a first domain binding an antigen on an antigen presenting cell (ARC) and a second domain binding an antigen on an immune cell expressing a chimeric antigen receptor (CAR). Nucleic acids, vectors and host cells used in producing the polypeptide of the invention are also disclosed. Compositions comprising the bispecific polypeptides and methods of treating cancer and stimulating activation and expansion of immune cells in vivo and in vitro are also disclosed.Type: ApplicationFiled: October 29, 2019Publication date: January 20, 2022Applicant: Peter MacCallum Cancer InstituteInventors: Michael Kershaw, Clare Slaney, Bianca Von Scheidt
-
Publication number: 20190300882Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of neuroblastoma, compositions comprising same, and use thereof to treat individuals suffering from neuroblastoma as a monotherapy or in combination with a chemotherapeutic agent. In particular, the present disclosure relates to microRNAs (miRNAs) which affect viability of neuroblastoma cells.Type: ApplicationFiled: June 7, 2017Publication date: October 3, 2019Applicants: GARVAN INSTITUTE OF MEDICAL RESEARCH, PETER MACCALLUM CANCER INSTITUTEInventors: Alex SWARBRICK, Iva NIKOLIC, Kaylene SIMPSON
-
Patent number: 9896663Abstract: Bromodomain and extra terminal protein (BET) resistant leukemic cell lines and methods for producing such cell lines are described as are methods for using such cell lines in screening assays to identify therapeutic agents. The cell lines can be generated from haematopoietic stem and progenitor cells (HSPCs) that are clonally enriched by serially exposing c-kit positive cells to a BET inhibitor.Type: GrantFiled: March 11, 2016Date of Patent: February 20, 2018Assignee: Peter MacCallum Cancer InstituteInventors: Mark A. Dawson, Chun Yew Fong
-
Patent number: 9896443Abstract: Compounds of formula (1a) and pharmaceutically acceptable salts, solvates, and hydrates thereof and related methods of modulatin perforin activity on a cell: wherein Ring A is selected from a 6-10 membered aryl, 5-6 membered cycloalkyi, 5-6 membered heteroaryl or 5-6 membered heterocyclyl, wherein the heteroaryl and heterocyclyl rings comprise at least one heteroatom selected from N, O or S; and wherein the aryl, cycloalkyi, heteroaryl or heterocyclyl rings are optionally substituted with 1 to 3 substituents selected from halo, nitro, —C1-Cealkyl, —C1-Ceaminoalkyl, —C1-C6hydroxyalkyl, -haloC1-C6alkyl, —C1-C6alkoxyl, -haloC1—C<aIkoxyl, heteroaryl, aryl, hydroxyl, —C(0)Ci-C6alkyl, —OC(0)Ci-C6alkyl, —CH2OC(O)CrC6alkyl, —C(O)OC1, —C6alkyI, —NHC(O)C1, —C6alkyl, —NHS(O)2C1-C6alkyl, —S(O)2C1-C6alkyl, —S(O)2NH2, and —C(O)NJJ; Ring B is a 6-10 membered arylene or a 5-6 membered heteroarylene comprising at least one heteroatom selected from N, 0 or S; and wherein the aryl or heteroaryl is optionally, substituted witType: GrantFiled: August 21, 2013Date of Patent: February 20, 2018Assignee: Peter MacCallum Cancer InstituteInventors: Julie Ann Spicer, William Alexander Denny, Christian Karl Miller, Patrick David O'Connor, Kristiina Huttunen, Joseph A. Trapani, Geoff Hill, Kylie Alexander
-
Patent number: 9862776Abstract: The present invention relates to antibodies and antigen-binding fragments thereof that bind RYK, in particular human RYK and their use in regulating RYK-associated activities. Specifically there is provided an isolated monoclonal antibody or antigen-binding fragment or derivative thereof that specifically binds to the extracellular domain of human RYK, in particular, the antibody or antigen-binding fragment thereof, binds specifically to the WIF domain of human RYK. Preferably, the antibodies of the present invention modulate RYK-associated activity, which includes RYK mediated signal transduction activity and modulation of the interaction of Wnts with RYK and, preferably, modulate Wnt induced signaling. In particular, the antibodies inhibit the binding of Wnt5a and inhibit Wnt induced phosphorylation of Dishevelled (Dvl) 2 and/or Dvl3 proteins.Type: GrantFiled: April 2, 2014Date of Patent: January 9, 2018Assignee: Peter MacCallum Cancer InstituteInventors: Maria Luisa Macheda, Michael Maurice Halford, Steven Stacker, Clare Louise Parish, Edouard Collins Nice
-
Patent number: 9724329Abstract: Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent.Type: GrantFiled: June 21, 2011Date of Patent: August 8, 2017Assignee: Peter MacCallum Cancer InstituteInventors: Andy Kang-Wei Hsu, Jake Shortt, Paul Neeson, Ricky Wayne Johnstone, David Ritchie
-
Patent number: 9718887Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.Type: GrantFiled: September 6, 2013Date of Patent: August 1, 2017Assignees: Adelaide Research & Innovation PTY LTD, Peter Maccallum Cancer InstituteInventors: Shaun Reuss Mccoll, Ian Comerford, Yuka Harata-Lee, Mark Smyth
-
Publication number: 20150291698Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.Type: ApplicationFiled: September 6, 2013Publication date: October 15, 2015Applicants: Peter MacCallum Cancer Institute, Adelaide Research & Innovation Pty LtdInventors: Shaun Reuss Mccoll, Ian Comerford, Yuka Harata-Lee, Mark Smyth
-
Patent number: 8999993Abstract: The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection).Type: GrantFiled: April 6, 2011Date of Patent: April 7, 2015Assignee: Peter MacCallum Cancer InstituteInventors: Roger Francis Martin, Jonathan White, Pavel Lobachevsky, David Winkler, Colin Skene, Sebastian Marcuccio
-
Patent number: 8796277Abstract: The invention relates to radioprotectors of formula (I), processes for their preparation and their use in protecting biological materials from radiation damage. In diagnostic and therapeutic radiology, particularly in cancer radiotherapy, the radioprotectors of the present invention may be used to protect certain normal tissues or structures from radiation damage. The radioprotectors of formula (I) may also have uses in decreasing the effects of irradiation in non-medical scenarios, both civil and military.Type: GrantFiled: December 21, 2007Date of Patent: August 5, 2014Assignee: Peter MacCallum Cancer InstituteInventors: Roger Francis Martin, Jonathan Michael White
-
Publication number: 20140128450Abstract: The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein.Type: ApplicationFiled: October 2, 2013Publication date: May 8, 2014Applicant: Peter MacCallum Cancer InstituteInventors: Ygal Haupt, Susan Haupt
-
Patent number: 8586557Abstract: The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein.Type: GrantFiled: March 25, 2010Date of Patent: November 19, 2013Assignee: Peter MacCallum Cancer InstituteInventors: Ygal Haupt, Susan Haupt
-
Publication number: 20130302377Abstract: Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent.Type: ApplicationFiled: June 21, 2011Publication date: November 14, 2013Applicant: PETER MACCALLUM CANCER INSTITUTEInventors: Andy Kang-Wei Hsu, Jake Shortt, Paul Neeson, Ricky Wayne Johnstone, David Ritchie
-
Publication number: 20130109678Abstract: The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection).Type: ApplicationFiled: April 6, 2011Publication date: May 2, 2013Applicant: PETER MACCALLUM CANCER INSTITUTEInventors: Roger Francis Martin, Jonathan White, Pavel Lobachevsky, David Winkler, Colin Skene, Sebastian Maruccio
-
Publication number: 20130065897Abstract: The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.Type: ApplicationFiled: December 22, 2010Publication date: March 14, 2013Applicant: PETER MACCALLUM CANCER INSTITUTEInventors: Julie Ann Spicer, Kristiina Maria Huttunen, Dani Michelle Lyons, Joseph Albert Trapani, Mark John Smyth, William Alexander Denny
-
Patent number: RE46943Abstract: The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection).Type: GrantFiled: February 10, 2017Date of Patent: July 10, 2018Assignee: PETER MACCALLUM CANCER INSTITUTEInventors: Roger Francis Martin, Jonathan White, Pavel Lobachevsky, David Winkler, Colin Skene, Sebastian Marcuccio